IPO - HeartSciences Inc.

Form Type: 253G2

Filing Date: 2025-03-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390025022456

Filing Summary: HeartSciences Inc. has filed an offering circular supplement for a best efforts offering of up to $15 million, comprising units that include shares of Series D Convertible Preferred Stock and warrants to purchase common stock. Each unit will be sold for $3.50, with a total of 4,285,714 units available. The warrants are exercisable within 36 months at a price of $5.00 per share. The offering is designed to fund the Company's initiatives to enhance the diagnostic capabilities of ECG through AI technology, particularly focusing on its proprietary MyoVista wavECG device. The document outlines the details of the offering including the proposed investment strategies, the expected proceeds, and the plans for utilizing the funds raised. HeartSciences aims to improve cardiac screening through innovative technologies and is in the process of preparing submissions for FDA approvals related to its devices, anticipating clearances that would allow for marketing in the U.S. The offering will include agent warrants and emphasizes that significant investment will be subject to minimum thresholds. The company recognizes the need for additional funding for future developments and marketing initiatives.

Document Link: View Document

Form Type: 1-A/A

Filing Date: 2025-03-03

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025018955

Filing Summary: HeartSciences Inc. has filed an updated offering statement (Form 1-A/A) regarding its initial public offering. The company is based in Southlake, TX, and aims to sell common stock and warrants to raise capital. The offering includes options to acquire shares of common stock at an exercise price of $5.15 per share, with a total of 2,500 shares available, valued at approximately $10,046 based on the Black Scholes valuation method. The firm has engaged various legal advisors and has provided comprehensive details about its financial positions and projections. The offering is being conducted under Regulation D, specifically Section 4(a)(2) of the Securities Act.

Document Link: View Document

Form Type: 1-A

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000121390025012899

Filing Summary: HeartSciences Inc. is filing for an Initial Public Offering (IPO) to list its common stock and warrants on The Nasdaq Capital Market. The common stock consists of 9,478,210 shares and warrants consist of 17,250 and 41,805 in two different categories. The offering includes other securities, tipped as ‘Convertible Preferred Stock’ and structured equity options. The total proceeds targeted by the offering amount to $15,000,000. The company's address is 550 Reserve Street, Suite 360, Southlake, TX 76092. The filing is prepared with compliance under Section 4(a)(2) of the Securities Act, adhering to Rule 506(b) of Regulation D. The companies involved in the underwriting process are Haskell & White LLP and Foley Shechter Ablovatskiy LLP.

Document Link: View Document